Simona Catozzi, Souad Assaad, Lidia Delrieu, Bertrand Favier, Elise Dumas, Anne-Sophie Hamy, Aurélien Latouche, Hugo Crochet, Jean-Yves Blay, Jimmy Mullaert, Annabelle Ballesta, Pierre Heudel
INTRODUCTION: Recent retrospective studies suggest potential large patient's benefit through proper timing of immune checkpoint blockers (ICB). The association between ICB treatment timing and patient survival, neoplastic response and toxicities was investigated, together with interactions with performance status (PS) and sex. METHODS: A cohort of patients with metastatic or locally advanced solid tumors, who received pembrolizumab, nivolumab, atezolizumab, durvalumab, or avelumab, alone or with concomitant chemotherapy, between November 2015 and March 2021, at the Centre Leon Bérard (France), was retrospectively studied...
January 22, 2024: European Journal of Cancer